Evaluating the role of Her-2 in endocrine therapy for breast cancer

( views:, downloads: )
WU Shi-kai()
SONG San-tai()
Journal Title:
Volume 18, Issue 05, 2006
Key Word:


  • [1]Witton C J,Reeves J R,Going J J,et al.Expression of the Her-1~ 4 family of receptor tyrosine kinases in breast cancer[J].J Pathol,2003,200(3):290-297.
  • [2]Borg A,Baldetorp B,Ferno M,et al.EebB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer[J].Cancer Lett,1994,8(2):137-144.
  • [3]Carlomagno C,Perrone F,Gallo C,et al.C-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early breast cancer without axillary lymph node metastases[J].J Clin Oncol,1996,14(10):2702-2707.
  • [4]Beerli R R,Hynes N E.Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities[J].J Biol Chem,1996,271(11):6071-6076.
  • [5]Graus-Porta D,Beerli R R,Daly J M,et al.ErbB-2,the preferred heterodimerization partner of all ErbB receptors,is a mediator of lateral signaling[J].EMBO J,1997,16(7):1647-1655.
  • [6]Pietras R J,Arboleda J,Reese D M,et al.Her-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells[J].Oncogene,1995,10(12):2435-2446.
  • [7]Menard S,Pupa S M,Campiglio M,er al.Biologic and therapeutic role of Her-2 in cancer[J].Oncogene,2003,22(42):6570-6578.
  • [8]Tagliabue E,Agresti R,Ghirelli C,et al.The early relapse of premenopausal patients after surgery for node-positive breast carcinoma[J].Breast Cancer Res Treat,2001,70(2):155-156.
  • [9]Tovey S,Dunne B,Witton G J,et al.Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer[J].Clin Cancer Res,2005,11(12):4835 -4842.
  • [10]Gago F E,Fanelli M A,Ciocca D R,et al.Co-expression of steroid hormone receptors (estrogen receptor α and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer:Clinical outcome following tamoxifen-based adjuvant therapy[J].J Steroid Biochem Mol Biol,2006,98(1):36-40.
  • [11]Colozza M,Azambuja E,Cardoso F,et al.Breast cancer:achievement systemic therapies in pre-genomic era[J].Oncologist,2006,11 (2):111-125.
  • [12]Goldhirsch A,Glick J H,Gelber R D,et al.Meeting highlight:international expert consensus on the primary therapy of early breast cancer 2005[J].Annals Oncol,2005,16(10):1569-1583.
  • [13]Laurentiis M,Arpino G,Massarelli E,et al.A meta-analysis on the Interaction between Her-2 expression and response to endocrine treatment in advanced breast cancer[J].Clin Cancer Res,2005,11(3):4741-4748.
  • [14]Piccart-Gebhart M J,Procter M,Leyland-Jone B,et al.Trastuzumab after adjuvant chemotherapy in Her-2-positive breast cancer[J].N Engl J Med,2005,353(16):1659-1672.
  • [15]Romond E H,Perez E A,Bryant J,et al.Trastuzumab plus adjuvant chemotherapy for operable Her-2-positive breast cancer[J].N Engl J Med,2005,353(16):1673-1684.
  • [16]Osborne C K,Shou J,Massarweh S,et al.Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer[J].Clin Cancer Res,2005,11(2 Pt 2):865-870.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn